Thank you for the question.
We used cost drivers that were published by the PMPRB over the previous four-year period. Multiple factors were considered in the growth. The major one was the cost of biologics, which was a large driver. For patented drugs, there was actually a decrease over the last four years of 1.8%. Most of the increase was due to extraordinary drugs to treat hep C: the direct-acting antivirals. That was a large proportion of the costs. The biologics were another large proportion.
We did factor in a decrease in the overall yearly cost for the direct-acting antivirals, but for biologics we factored in an increase over the five-year period. That's due to the higher costs of biologics when compared to other drugs.